Clinical Trial Update: Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant [Phase 1]

View source ↗

Summary

Phase 1 neoadjuvant trial targeting androgen signaling in AR-positive urothelial carcinoma of the bladder has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma of the Bladder

Snippet

Sponsor: Brown University | Conditions: Urothelial Carcinoma Bladder, Androgen Receptor Positive | Phase 1 | Status: TERMINATED